Drug intelligence / Profile preview

ALXN-1920

Development stage: Phase 2
Lead developer: Alexion Pharmaceuticals
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

ALXN-1920 is a recombinant fusion protein developed as a complement factor H modulator for the treatment of kidney disorders, specifically nephrological diseases. The drug is designed to target kidney-targeted factor H, which plays a role in regulating the alternative pathway of complement activation—a key process implicated in certain kidney diseases. It is administered via subcutaneous or intravenous routes and is currently in Phase 1 clinical development. The developer and manufacturer is Alexion Pharmaceuticals (a subsidiary of AstraZeneca), known for its focus on rare and severe disease therapies[1][2][3][5].

Other names: kidney-targeted factor H fusion protein

Targets

CFH (Complement factor H)

Beyond the preview

Go deeper on ALXN-1920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALXN-1920.

Explore the full profile